Form 4: Bionano Genomics Executive Jonathan V. Dixon Reports Stock Option Grant

Jonathan V. Dixon, General Counsel of Bionano Genomics, reports the acquisition of stock options.

Summary

• On March 14, 2025, Jonathan V. Dixon, General Counsel of Bionano Genomics, acquired stock options to purchase 6,559 shares of common stock at an exercise price of $3.47 per share.
• The options vest monthly over 48 months, beginning one month after the vesting commencement date, and will be fully vested and exercisable four years from that date.
• Following the transaction, Mr. Dixon directly owns 6,559 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding executive compensation, and does not contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of 48 months is typical for such grants, aligning executive incentives with long-term company performance.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment by aligning executive interests with those of shareholders.

Key Dates